First clinical outcomes for SCINTIX therapy in lung and bone tumors unveiled by RefleXion Medical
RefleXion Medical, an external‑beam theranostic oncology company, announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX® biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported Grade 2 or higher adverse events. The data represent the first prospective, multi-institutional evidence of SCINTIX therapy’s clinical impact.